ADC Therapeutics’ Zynlonta-glofitamab combination shows 88.7% response rate in Phase 1b lymphoma trial
ADCT•ADC Therapeutics reported an 88.7% response rate for its Zynlonta-glofitamab combination in a Phase 1b lymphoma trial. Updated LOTIS-7 results showed durable responses, supporting further Phase 3 investigation.
1. Trial results
Updated Phase 1b LOTIS-7 results showed durable responses with Zynlonta combined with glofitamab, and the combination had an 88.7% response rate. ADC Therapeutics said the findings support further Phase 3 investigation.
2. Other Zynlonta studies
Phase 3 LOTIS-5 showed Zynlonta with rituximab delayed disease progression versus R-GemOx in relapsed or refractory DLBCL, without significantly improving overall survival. A Phase 2 marginal zone lymphoma study showed durable complete responses with Zynlonta monotherapy, supporting potential expansion into additional treatment settings.
